February 2026 FDA Recall Adbry by Leo Pharma Inc
D-0339-2026 - Lack of Assurance of Sterility

This Class II drug recall was voluntarily initiated by Leo Pharma Inc on February 10, 2026 for the product Adbry. The FDA reported the reason for recall as lack of assurance of sterility. The product was distributed Nationwide and the recall is currently ongoing.

Recall Number: D-0339-2026

Reason for Recall
Lack of Assurance of Sterility: due to the presence of particulate matter in one unit from the lot, which lab tests have identified as wool fiber.
Initiated
02-10-2026
Reported
03-04-2026
Quantity
11,407 units

Recall Profile & Regulatory Data

Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Nationwide in the USA
Adbry, (tralokinumab-ldrm) injection, 300 mg/2mL, Packaged as a) 1 x Single dose Autoinjector, SAMPLE NOT FOR SALE, NDC 50222-350-91; b) 2 x Single dose Autoinjectors, NDC 50222-350-02; Rx only, Manufactured by: LEO Pharma A/S. Industriparken 55, DK-2750 Ballerup, Denmark, Distributed by: LEO Pharma Inc., Madison, NJ 07940, USA,

Batch or Lot Expiration Information

Lot# Lot: a) 003E24C, Exp 04/30/2027; b) 003E24A, Exp 04/30/2027.